Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI

Movement Disorders

Volumn 22, Issue 11, 2007, Pages 1615-1622

  Meyer, Chris ^a   Schmid, Gebhard ^a   Görlitz, Sabine ^a   Ernst, Monika ^a   Wilkens, Christian ^a   Wilhelms, Inga ^a   Kraus, Peter H ^a   Bauer, Peter ^b   Tomiuk, Jürgen ^b   Przuntek, Horst ^a   Mügge, Andreas ^a   Schöls, Ludger ^c  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cardiac MRI; Cardiomyopathy; Friedreich's ataxia; Outcome measure for intervention trials

Indexed keywords

ADOLESCENT; ADULT; ANALYTIC METHOD; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FRIEDREICH ATAXIA; GENETIC ANALYSIS; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INTERRATER RELIABILITY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 34748830533     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21590     Document Type: Article

References (41)

1. Epplen C, Epplen JT, Frank G, et al. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet 1997;99:834-836.
2. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620.
3. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
4. Dürr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996;335:1169-1175.
5. Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996;59:554-560.
6. Schöls L, Amoiridis G, Przuntek H, et al. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 1997;120(Part 12):2131-2140.
7. Friedreich. Über degenerative Atrophie der spinalen Hinterstränge. Arch Path Anat 1863;27:391-419.
8. Hewer R. The heart disease in Friedreich's ataxia. Brit Heart J 1969:5-14.
9. Cote M, Davignon A, Elias G, et al. Hemodynamic findings in Friedreich's ataxia. Can J Neurol Sci 1976;3:333-336.
10. Lorenz T, Kurtz C, Shapiro H. Cardiopathy in Friedreich's ataxia (spinal form of hereditary sclerosis). Arch Intern Med 1950;86:412-426.
11. Pitt G. On a case of Friedreich's disease. Its clinical history and post-mortem appearances. Guy's Hosp Rep 1886;44:369-394.
12. Mott FW. Case on Friedreich's disease, with autopsy and systematic microscopial examination of the nervous system. Arch Neurol Path lab LCC Asylums 1907;3:180-200.
13. Spiller WG. Friedreich's ataxia. J Nerv Ment Dis 1910;37:411-435.
14. Russel DS. Myocarditis in Friedreich's ataxia. J Path Bact 1946:739-747.
15. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999;354:477-479.
16. Schöls L, Vorgerd M, Schillings M, Skipka G, Zange J. Idebenone in patients with Friedreich ataxia. Neurosci Lett 2001;306:169-172.
17. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003;60:1676-1679.
18. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001;49:590-596.
19. Cooper JM, Schapira AH. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy. Biofactors 2003;18:163-171.
20. Schols L, Zange J, Abele M, et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 2005;112:789-796.
21. Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997;276:1709-1712.
22. Schulz JB, Dehmer T, Schöls L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000;55:1719-1721.
23. Tan G, Napoli E, Taroni F, Cortopassi C. Decreased expression fo genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 2003;12:1699-1711.
24. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA 1999;96:11492-11495.
25. Vorgerd M, Schols L, Hardt C, et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 2000;10:430-435.
26. Trouillas P, Takayanagi T, Hallett M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;12:205-211.
27. Schiller NB. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Commitee on Standards, Subcommittee on Quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:450-458.
28. Devereux RB, Alonso DR, Lutas EM. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57;2:450-458.
29. Cohen J. A coefficient of agreement for internal scales. Educ Psychol Meas 1960;20:37-46.
30. Landis J, Koch C. The measurement of observer agreement for categorial data. Biometrics 1977;33:159-174.
31. Stewart GA, Foster J, Cowan M, Rooney E. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999;56:2248-2253.
32. Dutka D, Donnelly J, Nihoyannopoulos P, Oakley C, Nunez D. Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Heart 1999;81:141-147.
33. Isnard R, Kalotka H, Durr A, et al. Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich's ataxia. Circulation 1997;95:2247-2249.
34. Bit-Avragim N, Perrot A, Schols L, et al. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. J Mol Med 2001;78:626-632.
35. Maione S, Giunta A, Filla A, et al. May age onset be relevant in the occurrence of left ventricular hypertrophy in Friedreich's ataxia? Clin Cardiol 1997;20:141-145.
36. Hausse A, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002;87:346-349.
37. Harding AE, Hewer RL. The heart disease of Friedreich's ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases. Q J Med 1983;52:489-502.
38. Hawley R, Gottdiener J. Five-year follow-up of Friedreich's ataxia cardiomyopathy. Arch Intern Med 1986;146:483-488.
39. Casazza F, Ferrari F, Piccone U, et al. Progression of cardiopathology in Friedreich's ataxia: clinico-instrumental study. Cardiologia 1990;35:423-431.
40. Casazza F, Morpurgo M. Progression of hypertrophic into a dilated left ventricle in Friedreich's ataxia. G Ital Cardiol. 1988;18:615-618.
41. Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology 2005;64:1261-1262.